Literature DB >> 19850148

The role of B cells in lupus pathogenesis.

Emil Nashi1, YingHua Wang, Betty Diamond.   

Abstract

Autoantibodies clearly contribute to tissue inflammation in systemic lupus erythematosus. In order to therapeutically target B cells making pathogenic autoantibodies, it is necessary to identify their phenotype. It is also important to understand the defects in B cell repertoire selection that permit pathogenic autoreactive B cells to enter the immunocompetent B cell repertoire. We present the data that both marginal zone and follicular B cells can produce pathogenic autoantibodies. Moreover, we discuss how B cell survival and maturation are regulated centrally prior to antigen activation and in the periphery after antigen activation to form the repertoire that generates the spectrum of circulating antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850148      PMCID: PMC2835836          DOI: 10.1016/j.biocel.2009.10.011

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  101 in total

1.  Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor.

Authors:  Brian P O'Connor; Laura A Vogel; Weijun Zhang; William Loo; Danielle Shnider; Evan F Lind; Michelle Ratliff; Randolph J Noelle; Loren D Erickson
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  TLR9 signaling in B cells determines class switch recombination to IgG2a.

Authors:  Andrea Jegerlehner; Patrik Maurer; Juliana Bessa; Heather J Hinton; Manfred Kopf; Martin F Bachmann
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

Review 3.  B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.

Authors:  Fabienne Mackay; Pablo A Silveira; Robert Brink
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

Review 4.  Protein tyrosine phosphatase PTPN22 in human autoimmunity.

Authors:  Torkel Vang; Ana V Miletic; Nunzio Bottini; Tomas Mustelin
Journal:  Autoimmunity       Date:  2007-09       Impact factor: 2.815

Review 5.  Mechanisms of killing by anti-CD20 monoclonal antibodies.

Authors:  Martin J Glennie; Ruth R French; Mark S Cragg; Ronald P Taylor
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

6.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Authors:  Frédéric Lavie; Corinne Miceli-Richard; Marc Ittah; Jérémie Sellam; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-10-13       Impact factor: 19.103

7.  Autoreactivity in human IgG+ memory B cells.

Authors:  Thomas Tiller; Makoto Tsuiji; Sergey Yurasov; Klara Velinzon; Michel C Nussenzweig; Hedda Wardemann
Journal:  Immunity       Date:  2007-02       Impact factor: 31.745

8.  Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.

Authors:  K P Ng; J J Manson; A Rahman; D A Isenberg
Journal:  Arthritis Rheum       Date:  2006-12-15

9.  Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.

Authors:  Mary Rieck; Adrian Arechiga; Suna Onengut-Gumuscu; Carla Greenbaum; Patrick Concannon; Jane H Buckner
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

10.  Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE.

Authors:  Meggan Mackay; Anfisa Stanevsky; Tao Wang; Cynthia Aranow; Margaret Li; Scott Koenig; Jeffrey V Ravetch; Betty Diamond
Journal:  J Exp Med       Date:  2006-08-21       Impact factor: 14.307

View more
  41 in total

1.  Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo.

Authors:  Anne Baerenwaldt; Anja Lux; Heike Danzer; Bernd M Spriewald; Evelyn Ullrich; Gordon Heidkamp; Diana Dudziak; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 2.  BAFF and selection of autoreactive B cells.

Authors:  Zheng Liu; Anne Davidson
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

3.  Serine/threonine phosphatase PP2A is essential for optimal B cell function.

Authors:  Esra Meidan; Hao Li; Wenliang Pan; Michihito Kono; Shuilian Yu; Vasileios C Kyttaris; Christina Ioannidis; Noe Rodriguez Rodriguez; Jose C Crispin; Sokratis A Apostolidis; Pui Lee; John Manis; Amir Sharabi; Maria G Tsokos; George C Tsokos
Journal:  JCI Insight       Date:  2020-03-12

4.  Expression of CCR6 on B cells in systemic lupus erythematosus patients.

Authors:  Adrian Y S Lee; Jennifer L Bannan; Murray J Adams; Heinrich Körner
Journal:  Clin Rheumatol       Date:  2017-04-25       Impact factor: 2.980

5.  Belimumab and the clinical data.

Authors:  Katrina Shum; Anca Askanase
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

6.  Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.

Authors:  Debasis Pore; Emily Huang; Dina Dejanovic; Neetha Parameswaran; Michael B Cheung; Neetu Gupta
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

7.  Cyclin-dependent kinase inhibitor Cdkn2c deficiency promotes B1a cell expansion and autoimmunity in a mouse model of lupus.

Authors:  Hari-Hara S K Potula; Zhiwei Xu; Leilani Zeumer; Allison Sang; Byron P Croker; Laurence Morel
Journal:  J Immunol       Date:  2012-08-15       Impact factor: 5.422

8.  Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.

Authors:  Ahmed Nader; Mukul Minocha; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

Review 9.  Belimumab in systemic lupus erythematosus: a perspective review.

Authors:  Joyce S Hui-Yuen; Xiao Q Li; Anca D Askanase
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

10.  Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice.

Authors:  Xin Wei; Gang Zhao; Xiaobei Wang; Nagsen Gautam; Zhenshan Jia; Zhifeng Zhao; Dexuan Kong; Fan Zhang; Sushil Kumar; Yuanyuan Sun; Ningrong Chen; Xiaoyan Wang; Libin Yang; Rongguo Ren; Geoffrey M Thiele; Tatiana K Bronich; James R O'Dell; Yazen Alnouti; Dong Wang
Journal:  Nanomedicine       Date:  2020-07-15       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.